Interestingly, the efficacy of c-Met-targeting agents has been associated with high c-Met expression in other tumors including non-small-cell lung cancer, hepatocellular carcinoma, and renal cell carcinoma [50–52]. The gene discussed is MET; the disease is hepatocellular carcinoma.